110 likes | 125 Views
ABSSSI is defined as a bacterial infection of Skin with a lesion size area of u226575 cm2. ABSSSIs consist of the most frequently diagnosed skin infections worldwide.<br>
E N D
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Market Insights, Epidemiology and Market Forecast- 2028
Acute Bacterial Skin and Skin-Structure Infection 01 02 03 04 ABSSSI is defined as a bacterial infection of Skin with a lesion size area of ≥75 cm2. ABSSSIs consist of the most frequently diagnosed skin infections worldwide. There are several pathogens that lead to ABSSSIs like Methicillin sensitive Staphylococcus aureus, Methicillin resistant Staphylococcus aureus, Beta-hemolytic Streptococcus, Escherichia coli and many others. ABSSSIs may be either community-acquired or hospital-acquired, and the predisposing factors include trauma, chronic cutaneous lesions, skin conditions, edema due to venous insufficiency, and immunosuppression. The serious ABSSSIs that need hospitalization for parenteral antibiotic therapy are identified based on the nature of the potential causative pathogens and host factors pointing to the severity of the disease. • DelveInsight © 2019 | All rights reserved
ABSSSI Epidemiology In the United States, more than 15 million bacterial skin and skin structure infections occur. 1 2 Acute Bacterial Skin and Skin Structure Infections total 7MM Incident cases were 7,259,777in 2017. 3 There were 1,942,229 male patients and 1,406,442female cases suffering from ABSSSI in 2017 in the United States. 4 A total of 1.8% of hospital admissions for 2005 to 2011 were for adult patients with a SSSI primary diagnosis. • DelveInsight © 2019 | All rights reserved
ABSSSI Market Outlook The major subtype of ABSSSI is cellulitis for which the treatment involves an oral antibiotic with activity against streptococci. Major treatment options for mild cases of non-purulent infections include penicillin, amoxicillin, amoxicillin-clavulanate, dicloxacillin, cephalexin, and clindamycin. ABSSSI treatment usually includes an antimicrobial therapy, surgical drainage, and antibiotic therapy. The therapeutic approaches favored in treating skin infections include adjunctive therapies, early and appropriate empiric antibiotic therapy, wound culture with susceptibility testing and surgical drainage and debridement. ABSSSI treatment is quite difficult, as there is an increased antimicrobial resistance b between Gram-positive and Gram-negative bacteria with methicillin-resistant, but the treatment continues to be antimicrobial therapies combined with appropriate surgical intervention. Oral and intravenous options for ABSSSI treatment for activity against Methicillin resistant Staphylococcus aureus (MRSA), include several long-standing therapies, such as sulfamethoxazole-trimethoprim, clindamycinand many others. • DelveInsight © 2019 | All rights reserved
ABSSSI Emerging Drugs and Companies Drug- Iclaprim Company- Motif Bio Drug-Brilacidin Company- Innovation Pharmaceuticals Drug- Ceftobiprole medocaril Company- Basilea Pharmaceutica Drug- Sodium Fusidate Company- Arrevus • DelveInsight © 2019 | All rights reserved
Complete Information For complete information on ABSSSI Market Insights, Epidemiology and Market Forecast-2028 please click the link below Click here OR Write Us At info@delveinsight.com • DelveInsight © 2019 | All rights reserved
About DelveInsight VISION ABOUT To be the most trusted market research & business consulting firm in the world; and to continue enable the Pharma & Bio-Tech companies to achieve their goals with the best strategic insight and competitive solution. The vision also is inclusive of becoming a one-stop solution provider for the entire gamut of drug development process. DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors. MISSION MISSION To provide “insights across the value chain” and helping the organization to take a prudent business decision through the use and analysis of actionable market intelligence. The mission also is to provide the most effective result and efficient service with utmost client care for maintaining a long-term relationship with them. • DelveInsight © 2019 | All rights reserved
About DelveInsight VISION ABOUT MISSION To be the most trusted market research & business consulting firm in the world; and to continue enable the Pharma & Bio-Tech companies to achieve their goals with the best strategic insight and competitive solution. The vision also is inclusive of becoming a one-stop solution provider for the entire gamut of drug development process. DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for improving their performances to stay ahead of the competitors. To provide “insights across the value chain” and helping the organization to take a prudent business decision through the use and analysis of actionable market intelligence. The mission also is to provide the most effective result and efficient service with utmost client care for maintaining a long-term relationship with them. • DelveInsight © 2019 | All rights reserved
Service Offerings by DelveInsight OPPORTUNITY ASSESSMENT 1 5 FORECASTING 2 6 REPORT STORE PIPELINE 7 3 PHARMDELVE CONSULTING MARKET INTELLIGENCE 8 COMPETITIVE ANALYSIS 4 • DelveInsight © 2019 | All rights reserved
Contact Us blog/delveInsight/ info@delveinsight.com +91-11-4568 9769 twitter/delveInsight LinkedIn/delveInsight www.delveinsight.com • DelveInsight © 2019 | All rights reserved